研究单位：[1]Peking University Hospital of Stomatology[2]Peking University School and Hospital Stomatology,Beijing,Beijing,China,100000[3]Affiliated Hospital of Hebei University,Baoding,Hebei,China[4]Tangshan People's Hospital,Tangshan,Hebei,China[5]The First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,China[6]Affiliated Hospital of Chifeng College,Chifeng,Inner Mongolia,China[7]The Affiliated Hospital of Inner Mongolia Medical University,Hohhot,Inner Mongolia,China[8]The Hospital of Stomatology of Jilin University,Changchun,Jilin,China[9]China Medical University School and Hospital Of Stomatology,Shenyang,Liaoning,China[10]Shandong Provincial Hospital,Jinan,Shandong,China[11]Shandong Provincial Hospital,Jinan,Shandong,China[12]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China[13]First Hospital of Shanxi Medical University,Taiyuan,Shanxi,China[14]Shanxi Cancer hospital,Taiyuan,Shanxi,China[15]Tianjin First Central Hospital,Tianjin,Tianjin,China
研究目的：
Previous studies confirmed locally advanced oral/oropharyngeal squamous cell carcinoma (LA OSCC or OPSCC) patients with a pathological response had higher probability of survival in neoadjuvant settings. Several ongoing trials of neoadjuvant immunotherapy in head and neck cancer showed promising results. However, the optimal regimen remains unclear. This trial aimed to evaluate the efficacy and safety of neoadjuvant therapy with anti-programmed cell death 1 monoclonal antibody Tislelizumab and chemotherapy, followed by surgery and adjuvant radiotherapy or chemoradiotherapy plus Tislelizumab in LA OSCC or OPSCC.
